Chromium Glycerylphosphate
Chromium glycerylphosphate is a compound combining the essential trace mineral chromium with glycerophosphate, theoretically designed to enhance chromium bioavailability and support glucose metabolism via insulin signaling pathways. As a relatively obscure chromium chelate, it lacks dedicated clinical research, making its specific efficacy profile largely extrapolated from broader chromium supplementation literature.
Origin & History
Chromium glycerylphosphate is a chromium compound chelated with glycerol phosphate molecules. Based on the limited research available, this appears to be a specialized mineral form combining the trace element chromium with glycerol phosphate compounds. The production process and commercial availability of this specific compound are not documented in the available research.
Historical & Cultural Context
No historical or traditional use information for chromium glycerylphosphate was found in the provided research. The research dossier contains no documentation of this compound's use in any traditional medicine system or historical context.
Health Benefits
• No specific health benefits can be cited from the provided research as chromium glycerylphosphate was not studied in the available literature • The research dossier only contains information about glycerol phosphate compounds in isolation • Clinical evidence for this specific chromium form is absent from the provided studies • No meta-analyses or RCTs were found examining chromium glycerylphosphate • Health benefit claims cannot be substantiated without proper clinical research
How It Works
Chromium, as the active mineral component, is believed to potentiate insulin receptor tyrosine kinase activity by facilitating the binding of the chromium-binding oligopeptide chromodulin to the insulin receptor, amplifying downstream glucose transporter GLUT-4 translocation to cell membranes. The glycerophosphate moiety may serve as a carrier ligand to improve intestinal absorption and cellular uptake compared to inorganic chromium salts. However, no published mechanistic studies have specifically characterized the intracellular behavior or receptor interactions unique to the glycerylphosphate chelate form of chromium.
Scientific Research
No clinical trials or meta-analyses examining chromium glycerylphosphate were found in the research dossier. The available studies focused solely on glycerol phosphate compounds without any connection to chromium supplementation. Without access to specific PMIDs or clinical data for this ingredient, evidence-based claims cannot be made.
Clinical Summary
No published randomized controlled trials, observational studies, or pharmacokinetic investigations specifically examine chromium glycerylphosphate as an isolated intervention. General chromium supplementation research, primarily using chromium picolinate and chromium polynicotinate at doses of 200–1000 mcg/day, has shown modest effects on fasting glucose and HbA1c in individuals with type 2 diabetes or insulin resistance, though effect sizes are generally small and study quality is mixed. A 2014 Cochrane-adjacent systematic review of chromium supplementation found insufficient evidence to recommend chromium for glycemic control in the general population. Until form-specific trials are conducted for chromium glycerylphosphate, its clinical utility cannot be independently established beyond inference from general chromium research.
Nutritional Profile
Chromium glycerylphosphate (also known as chromium glycerophosphate) is an organically-bound mineral salt providing trivalent chromium (Cr³⁺) complexed with glycerophosphoric acid. Approximate chromium content: ~12–14% elemental chromium by weight (varies by manufacturer specification, typically standardized to deliver a known Cr³⁺ dose per gram). The glycerophosphate moiety contributes trace amounts of phosphorus (~10–12% by weight) and a glycerol backbone. No significant macronutrient contribution (negligible calories, protein, fat, or carbohydrate) at supplemental doses (typically 200–1000 µg elemental chromium per day). Contains no vitamins, fiber, or other bioactive compounds beyond the chromium ion and the glycerophosphate carrier. Bioavailability notes: Organically-bound chromium forms (such as picolinate, nicotinate, and glycerophosphate) are generally considered to have superior absorption compared to inorganic chromium chloride (CrCl₃), which has bioavailability of only ~0.4–2.0%. Glycerophosphate salts are recognized for enhanced solubility and gastrointestinal tolerability compared to inorganic mineral salts, potentially improving passive and active intestinal absorption. However, direct pharmacokinetic studies specifically quantifying the bioavailability of chromium glycerylphosphate versus other chromium forms (e.g., chromium picolinate at ~2–5% absorption) are lacking in published literature. The glycerophosphate ligand is hydrolyzed in the gut to glycerol and inorganic phosphate, which may facilitate chromium release for absorption in the duodenum and jejunum. Total body chromium stores are estimated at 4–6 mg in adults; adequate intake (AI) is set at 25 µg/day for adult women and 35 µg/day for adult men (per IOM). Chromium is an ultra-trace mineral with no established RDA, and the tolerable upper intake level (UL) has not been formally set due to insufficient toxicity data for trivalent chromium forms.
Preparation & Dosage
No clinically studied dosage ranges for chromium glycerylphosphate were identified in the research. Without clinical trial data or safety studies, appropriate dosing cannot be determined. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Cannot be determined without clinical research
Safety & Interactions
Chromium supplementation broadly is considered well tolerated at doses up to 1000 mcg/day, with the most commonly reported adverse effects being gastrointestinal discomfort, headache, and insomnia at higher doses. Chromium may potentiate the hypoglycemic effects of insulin, metformin, and sulfonylureas, requiring careful blood glucose monitoring in diabetic patients using these medications. The glycerophosphate ligand itself has no established significant toxicity, though individuals with severe renal impairment should exercise caution with any phosphate-containing compound. Chromium supplementation during pregnancy and lactation is not well studied and is generally advised only under direct medical supervision.